Literature DB >> 25380529

Limbal Fibroblasts Maintain Normal Phenotype in 3D RAFT Tissue Equivalents Suggesting Potential for Safe Clinical Use in Treatment of Ocular Surface Failure.

Isobel Massie1, Sarah B Dale1, Julie T Daniels1.   

Abstract

Limbal epithelial stem cell deficiency can cause blindness, but transplantation of these cells on a carrier such as human amniotic membrane can restore vision. Unfortunately, clinical graft manufacture using amnion can be inconsistent. Therefore, we have developed an alternative substrate, Real Architecture for 3D Tissue (RAFT), which supports human limbal epithelial cells (hLE) expansion. Epithelial organization is improved when human limbal fibroblasts (hLF) are incorporated into RAFT tissue equivalent (TE). However, hLF have the potential to transdifferentiate into a pro-scarring cell type, which would be incompatible with therapeutic transplantation. The aim of this work was to assess the scarring phenotype of hLF in RAFT TEs in hLE+ and hLE- RAFT TEs and in nonairlifted and airlifted RAFT TEs. Diseased fibroblasts (dFib) isolated from the fibrotic conjunctivae of ocular mucous membrane pemphigoid (Oc-MMP) patients were used as a pro-scarring positive control against which hLF were compared using surrogate scarring parameters: matrix metalloproteinase (MMP) activity, de novo collagen synthesis, α-smooth muscle actin (α-SMA) expression, and transforming growth factor-β (TGF-β) secretion. Normal hLF and dFib maintained different phenotypes in RAFT TE. MMP-2 and -9 activity, de novo collagen synthesis, and α-SMA expression were all increased in dFib cf. normal hLF RAFT TEs, although TGF-β1 secretion did not differ between normal hLF and dFib RAFT TEs. Normal hLF do not progress toward a scarring-like phenotype during culture in RAFT TEs and, therefore, may be safe to include in therapeutic RAFT TE, where they can support hLE, although in vivo work is required to confirm this. dFib RAFT TEs (used in this study as a positive control) may be useful toward the development of an ex vivo disease model of Oc-MMP.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25380529      PMCID: PMC4442587          DOI: 10.1089/ten.TEC.2014.0458

Source DB:  PubMed          Journal:  Tissue Eng Part C Methods        ISSN: 1937-3384            Impact factor:   3.056


  38 in total

Review 1.  Limbal stem cell deficiency: concept, aetiology, clinical presentation, diagnosis and management.

Authors:  H S Dua; J S Saini; A Azuara-Blanco; P Gupta
Journal:  Indian J Ophthalmol       Date:  2000-06       Impact factor: 1.848

Review 2.  Myofibroblasts and mechano-regulation of connective tissue remodelling.

Authors:  James J Tomasek; Giulio Gabbiani; Boris Hinz; Christine Chaponnier; Robert A Brown
Journal:  Nat Rev Mol Cell Biol       Date:  2002-05       Impact factor: 94.444

Review 3.  Apoptosis in the initiation, modulation and termination of the corneal wound healing response.

Authors:  Steven E Wilson; Shyam S Chaurasia; Fabricio W Medeiros
Journal:  Exp Eye Res       Date:  2007-06-21       Impact factor: 3.467

4.  The variation in transparency of amniotic membrane used in ocular surface regeneration.

Authors:  C J Connon; J Doutch; B Chen; A Hopkinson; J S Mehta; T Nakamura; S Kinoshita; K M Meek
Journal:  Br J Ophthalmol       Date:  2009-03-19       Impact factor: 4.638

5.  Profibrotic phenotype of conjunctival fibroblasts from mucous membrane pemphigoid.

Authors:  Valerie P J Saw; Enno Schmidt; Ifeoma Offiah; Grazyna Galatowicz; Detlef Zillikens; John K G Dart; Virginia L Calder; Julie T Daniels
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

Review 6.  Corneal stromal wound healing in refractive surgery: the role of myofibroblasts.

Authors:  J V Jester; W M Petroll; H D Cavanagh
Journal:  Prog Retin Eye Res       Date:  1999-05       Impact factor: 21.198

7.  The compliance of collagen gels regulates transforming growth factor-beta induction of alpha-smooth muscle actin in fibroblasts.

Authors:  P D Arora; N Narani; C A McCulloch
Journal:  Am J Pathol       Date:  1999-03       Impact factor: 4.307

8.  Cytokine profile and supposed contribution to scarring in cicatricial pemphigoid.

Authors:  Marzia Caproni; Anna Calzolari; Elisabetta Salvatore; Barbara Giomi; Walter Volpi; Alberino D'Agata; Marco Santucci; Paolo Fabbri
Journal:  J Oral Pathol Med       Date:  2003-01       Impact factor: 4.253

9.  Corneal stromal cell plasticity: in vitro regulation of cell phenotype through cell-cell interactions in a three-dimensional model.

Authors:  Samantha L Wilson; Ying Yang; Alicia J El Haj
Journal:  Tissue Eng Part A       Date:  2013-09-09       Impact factor: 3.845

10.  Connective tissue remodeling in corneal and scleral wounds.

Authors:  P F Davison; E J Galbavy
Journal:  Invest Ophthalmol Vis Sci       Date:  1986-10       Impact factor: 4.799

View more
  5 in total

Review 1.  Engineering epithelial-stromal interactions in vitro for toxicology assessment.

Authors:  David G Belair; Barbara D Abbott
Journal:  Toxicology       Date:  2017-03-08       Impact factor: 4.221

Review 2.  Regenerative therapy for the Cornea.

Authors:  Ajay Kumar; Hongmin Yun; Martha L Funderburgh; Yiqin Du
Journal:  Prog Retin Eye Res       Date:  2021-09-14       Impact factor: 21.198

3.  Compressed Collagen Enhances Stem Cell Therapy for Corneal Scarring.

Authors:  Golnar Shojaati; Irona Khandaker; Kyle Sylakowski; Martha L Funderburgh; Yiqin Du; James L Funderburgh
Journal:  Stem Cells Transl Med       Date:  2018-04-14       Impact factor: 6.940

Review 4.  A Scoping Review of the Role of Metalloproteinases in the Pathogenesis of Autoimmune Pemphigus and Pemphigoid.

Authors:  Nicola Cirillo; Stephen S Prime
Journal:  Biomolecules       Date:  2021-10-13

5.  Real architecture For 3D Tissue (RAFT™) culture system improves viability and maintains insulin and glucagon production of mouse pancreatic islet cells.

Authors:  Gabor J Szebeni; Zsuzsanna Tancos; Liliana Z Feher; Robert Alfoldi; Julianna Kobolak; Andras Dinnyes; Laszlo G Puskas
Journal:  Cytotechnology       Date:  2017-02-08       Impact factor: 2.058

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.